Bit Bio Snapshot
bit. bio's mission is to code cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell.
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox™; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.
The required transcription factor combinations are discovered using high throughput screens and advanced data analysis (bit.bio discovery platform). Currently the company is marketing six ioCells research products and building a clinical pipeline.
The company was spun out of the University of Cambridge in 2016 and has since raised $150M capital from Arch Ventures, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Puhua Capital among others.
The required transcription factor combinations are discovered using high throughput screens and advanced data analysis (bit.bio discovery platform). Currently the company is marketing six ioCells research products and building a clinical pipeline.
The company was spun out of the University of Cambridge in 2016 and has since raised $150M capital from Arch Ventures, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Puhua Capital among others.
